MedPath

Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma

Phase 3
Completed
Conditions
Sarcoma
Registration Number
NCT00002539
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. It is not yet known whether chemotherapy and surgery plus G-CSF is more effective than chemotherapy and surgery alone in treating patients with osteosarcoma.

PURPOSE: Randomized phase III trial to compare the effectiveness combination chemotherapy and surgery with or without G-CSF in treating patients who have newly diagnosed osteosarcoma.

Detailed Description

OBJECTIVES:

* Determine the overall and disease-free survival of patients with newly diagnosed osteosarcoma of the extremity treated with conventional vs intensive cisplatin and doxorubicin with or without filgrastim (G-CSF) before and after definitive surgery.

* Compare the toxicity of these regimens in these patients.

* Compare the response in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive conventional doxorubicin (DOX) IV over 4 hours on days 1-3 and cisplatin (CDDP) IV continuously on day 1. Treatment continues every 3 weeks for 2 courses. At week 6, patients undergo amputation or local resection based on pretherapy imaging and response to chemotherapy. Beginning 2 weeks after surgery, patients receive 4 additional courses of conventional chemotherapy.

* Arm II: Patients receive intensive DOX and CDDP as above on day 1 plus filgrastim (G-CSF) subcutaneously on days 4-13. Treatment continues every 2 weeks for 3 courses. At week 6, patients undergo definitive surgery as in arm I. Beginning 2 weeks after surgery, patients receive 3 additional courses of intensive DOX and CDDP with G-CSF.

Patients who experience disease progression during preoperative chemotherapy undergo surgery earlier than scheduled and complete all scheduled chemotherapy (6 courses) after surgery, at the discretion of the surgeon and oncologist. Within 4 weeks after limb-sparing procedure, patients with inadequate margins undergo amputation, followed 2 weeks later by chemotherapy.

Patients are followed monthly for 6 months, every 2 months for 6 months, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
214
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (16)

University Medical Center Nijmegen

🇳🇱

Nijmegen, Netherlands

Academisch Ziekenhuis Utrecht

🇳🇱

Utrecht, Netherlands

Institut Jules Bordet

🇧🇪

Brussels (Bruxelles), Belgium

Cliniques Universitaires Saint-Luc

🇧🇪

Brussels (Bruxelles), Belgium

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Centre Eugene Marquis

🇫🇷

Rennes, France

Onze Lieve Vrouwe Gasthuis

🇳🇱

Amsterdam, Netherlands

Emma Kinderziekenhuis

🇳🇱

Amsterdam, Netherlands

Instituto Portugues de Oncologia de Francisco Gentil-Centro de Lisboa

🇵🇹

Lisbon, Portugal

King Faisal Specialist Hospital and Research Centre

🇸🇦

Riyadh, Saudi Arabia

Institute of Oncology, Ljubljana

🇸🇮

Ljubljana, Slovenia

St. James's Hospital

🇬🇧

Leeds, England, United Kingdom

Aarhus Kommunehospital

🇩🇰

Aarhus, Denmark

Rigshospitalet

🇩🇰

Copenhagen, Denmark

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

© Copyright 2025. All Rights Reserved by MedPath